NO20052281L - Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden - Google Patents

Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden

Info

Publication number
NO20052281L
NO20052281L NO20052281A NO20052281A NO20052281L NO 20052281 L NO20052281 L NO 20052281L NO 20052281 A NO20052281 A NO 20052281A NO 20052281 A NO20052281 A NO 20052281A NO 20052281 L NO20052281 L NO 20052281L
Authority
NO
Norway
Prior art keywords
application
amphiphates
deformability
aggregate
vivo
Prior art date
Application number
NO20052281A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052281D0 (no
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,617 external-priority patent/US7473432B2/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of NO20052281D0 publication Critical patent/NO20052281D0/no
Publication of NO20052281L publication Critical patent/NO20052281L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
NO20052281A 2002-10-11 2005-05-10 Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden NO20052281L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Publications (2)

Publication Number Publication Date
NO20052281D0 NO20052281D0 (no) 2005-05-10
NO20052281L true NO20052281L (no) 2005-07-07

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052281A NO20052281L (no) 2002-10-11 2005-05-10 Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden

Country Status (22)

Country Link
EP (5) EP1815847A3 (xx)
JP (3) JP2006505619A (xx)
KR (1) KR20050055723A (xx)
CN (1) CN1703199B (xx)
AT (1) ATE381316T1 (xx)
AU (1) AU2003273977B2 (xx)
BR (1) BR0315148A (xx)
CA (1) CA2498938A1 (xx)
DE (1) DE60318227T2 (xx)
DK (1) DK1551370T3 (xx)
EA (1) EA010407B1 (xx)
ES (1) ES2298566T3 (xx)
HK (1) HK1079113A1 (xx)
HR (1) HRPK20050421B3 (xx)
IS (1) IS7776A (xx)
MX (1) MXPA05003744A (xx)
NO (1) NO20052281L (xx)
NZ (1) NZ538571A (xx)
PL (1) PL377202A1 (xx)
PT (1) PT1551370E (xx)
SI (1) SI1551370T1 (xx)
WO (1) WO2004032900A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
KR20070086045A (ko) * 2004-11-12 2007-08-27 이데아 아게 피부 상태 치료에서의 확대된 표면 집합체
CA2698293A1 (en) * 2007-09-13 2009-03-26 Thomas Subkowski Use of hydrophobin polypeptides as penetration intensifiers
PL214538B1 (pl) 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
EA029132B1 (ru) * 2009-06-03 2018-02-28 Секвессам Текнолоджи Холдингс Лимитед Составы в виде везикул для лечения боли, связанной с остеоартритом
NZ598906A (en) * 2009-08-21 2014-08-29 Targeted Delivery Technologies Ltd Vesicular formulations
DE112012001386T5 (de) * 2011-03-21 2013-12-19 Gregor Cevc Optimierte Präparate von sehr anpassungsfähigen Aggregaten
WO2012126965A1 (en) * 2011-03-21 2012-09-27 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CA2889664C (en) * 2012-10-26 2020-12-29 Oxford Nanopore Technologies Limited Droplet interfaces
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
CN114949237A (zh) * 2013-07-31 2022-08-30 斯昆申技术控股有限责任公司 囊泡
US10175256B2 (en) * 2013-09-26 2019-01-08 National University Of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
CN105658782B (zh) * 2013-10-25 2018-08-07 凸版印刷株式会社 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法
EP3954361A1 (en) 2015-06-30 2022-02-16 Sequessome Technology Holdings Limited Multiphasic compositions
EP3606557A4 (en) * 2017-04-03 2020-12-16 The Regents of The University of California MOLDABLE NANOSCALE CARRIERS (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN BARRIER, MUCCOUS AND SKIN
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE4447277A1 (de) * 1994-12-30 1996-07-04 Hoechst Ag Stabilisierte, phosphormodifizierte Epoxidharze und ihre Verwendung
DE69825495T2 (de) * 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
ATE216223T1 (de) * 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern

Also Published As

Publication number Publication date
HRPK20050421B3 (en) 2007-06-30
AU2003273977B2 (en) 2007-07-12
BR0315148A (pt) 2005-08-16
ES2298566T3 (es) 2008-05-16
HK1079113A1 (en) 2006-03-31
PT1551370E (pt) 2008-02-07
EA200500632A1 (ru) 2005-12-29
EP1815847A3 (en) 2008-11-05
CA2498938A1 (en) 2004-04-22
AU2003273977A1 (en) 2004-05-04
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
NZ538571A (en) 2007-05-31
JP2009108070A (ja) 2009-05-21
WO2004032900A1 (en) 2004-04-22
EP1815846A3 (en) 2008-10-22
JP2005213261A (ja) 2005-08-11
EP1829527A3 (en) 2008-11-05
KR20050055723A (ko) 2005-06-13
WO2004032900A8 (en) 2005-03-31
IS7776A (is) 2005-03-30
NO20052281D0 (no) 2005-05-10
HRP20050421A2 (en) 2005-12-31
MXPA05003744A (es) 2005-09-20
JP2006505619A (ja) 2006-02-16
CN1703199A (zh) 2005-11-30
EP1551370A1 (en) 2005-07-13
JP4555111B2 (ja) 2010-09-29
ATE381316T1 (de) 2008-01-15
PL377202A1 (pl) 2006-01-23
CN1703199B (zh) 2010-04-28
EA010407B1 (ru) 2008-08-29
EP1815847A2 (en) 2007-08-08
EP1829527A2 (en) 2007-09-05
SI1551370T1 (sl) 2008-06-30
DE60318227T2 (de) 2008-12-04
EP1551370B1 (en) 2007-12-19
DE60318227D1 (de) 2008-01-31
EP1815846A2 (en) 2007-08-08
EP1829528A3 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
NO20052281D0 (no) Aggregat med okt deformerbarhet omfattende minst tre amfipater for forbedret transport gjennom semi-permeable membraner og for noninvasiv anvendelse av legemiddel in vivo, spesielt gjennom huden
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
WO2004019921A3 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
DE3786005D1 (de) Traeger zur freisetzung mit einem an eine amphiphile substanz gekoppelten wirkstoff.
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
EE04905B1 (et) Pridasino[4,5-b]indool-1-atseetamiidi derivaatide kasutamine ravimite valmistamiseks perifeersete bensodiasepiiniretseptorite dsfunktsioneerimisegaseotud haiguste raviks
DE69316379D1 (de) Morphogeninduzierte regenerierung der leber
ITTO930661A0 (it) Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
Labi et al. The Grief Brigade.
Derynck et al. Cell differentiation
Arenas-Marquez et al. Mexican consensus on the integral management of digestive tract fistulas. Ixtapa-Zihuatanejo, Mexico, August 21-23, 1997
WO2001017582A3 (en) Bifurcated shunt drug delivery system and methods of use
EP0400243A1 (fr) Elément prophylactique, tel que drain, doté d'une structure de diffusion in situ d'un produit thérapeutique, notamment d'un agent anti-microbien
HK1027762A1 (en) Use of hydrophilic solvent extract of mushroom in the preparation of drug or food for preventing andtreating kidney disease.
IS7259A (is) 3-Heteróarýl-3,5-díhýdró-4-oxó-4H-pýridasínó[4,5-b]indól-1-karboxamíð afleiður, framleiðsla þeirra og notkun þeirra við meðhöndlun
ES2135476T3 (es) Utilizacion de remacemida para el tratamiento de la enfermedad de parkinson.
WO2002000170A3 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
SE9902317D0 (sv) Bår
Booth Managing partnerships seen as future technology
SOBUE Points of View for the Future of Rehabilitation Medicine and Practice, Looking back on the Past 40 Years Activities
RU2001100160A (ru) Алгоритм выбора методики сочетанной медикаментозно-лазерной терапии
RU99103901A (ru) Способ медикаментозного лечения злокачественных опухолей

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application